Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Praluent Lives On As US Court Vacates Amgen's PCSK9 Patent Win

Executive Summary

While sales of Sanofi/Regeneron's Praluent, which will remain on the US market for the time being, could see a small boost, larger commercial challenges in the PCSK9 category linger.


Related Content

Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK
Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now
‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts